Sysmex Co. (OTCMKTS:SSMXY - Get Free Report) was the target of a large drop in short interest in May. As of May 31st, there was short interest totalling 600 shares, a drop of 97.9% from the May 15th total of 28,200 shares. Based on an average trading volume of 158,100 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company's stock are short sold.
Sysmex Stock Down 1.3%
OTCMKTS:SSMXY traded down $0.22 during midday trading on Friday, hitting $17.24. 43,044 shares of the company were exchanged, compared to its average volume of 71,452. Sysmex has a fifty-two week low of $14.38 and a fifty-two week high of $22.00. The company has a market capitalization of $10.85 billion, a PE ratio of 30.79 and a beta of 1.14. The company has a current ratio of 3.19, a quick ratio of 2.42 and a debt-to-equity ratio of 0.11. The company has a fifty day simple moving average of $17.77 and a 200 day simple moving average of $18.48.
Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.04). The firm had revenue of $958.89 million for the quarter, compared to analyst estimates of $991.22 million. As a group, equities analysts anticipate that Sysmex will post 0.57 earnings per share for the current fiscal year.
About Sysmex
(
Get Free Report)
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.
Further Reading
Before you consider Sysmex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.
While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
